Suppr超能文献

21242例丙型肝炎基因1型患者接受全口服治疗的真实世界疗效及持续病毒学应答的预测因素

Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients.

作者信息

Backus Lisa I, Belperio Pamela S, Shahoumian Troy A, Loomis Timothy P, Mole Larry A

机构信息

Department of Veterans Affairs, Population Health Services, Palo Alto Health Care System, Palo Alto, CA, USA.

出版信息

Antivir Ther. 2017;22(6):481-493. doi: 10.3851/IMP3117. Epub 2016 Dec 9.

Abstract

BACKGROUND

Predictors of sustained virological response (SVR) to all-oral HCV regimens can inform nuanced treatment decisions. We evaluated effectiveness and identified predictors of SVR for ledipasvir/sofosbuvir ± ribavirin (LDV/SOF ±RBV) and ombitasvir/paritaprevir/ritonavir + dasabuvir (OPrD) ±RBV in patients treated in routine practice.

METHODS

Observational, intent-to-treat cohort of 21,142 genotype-1 patients initiating 8 or 12 weeks of LDV/SOF ±RBV or 12 weeks of OPrD ±RBV at any Veterans Affairs facility. Multivariate logistic regression models were constructed to model SVR and identify predictors.

RESULTS

SVR was 91.2% (9,781/10,720) for LDV/SOF, 89.6% (3,266/3,646) for LDV/SOF+RBV, 91.7% (1,197/1,306) for OPrD and 87.8% (3,365/3,832) for OPrD+RBV. For LDV/SOF ±RBV, reduced odds of SVR occurred in African-Americans (0.80, 95% CI 0.70, 0.92, P<0.001), body mass index (BMI)<25 (0.77, 95% CI 0.66, 0.90, P<0.001), BMI≥30 (0.77, 95% CI 0.67, 0.89, P<0.001), proton pump inhibitors (PPIs; 0.81, 95% CI 0.71, 0.92, P<0.001), decompensated liver disease (0.58, 95% CI 0.45, 0.74, P<0.001) and FIB4>3.25 (0.60, 95% CI 0.53, 0.69, P<0.001). For OPrD ±RBV, FIB-4>3.25 negatively predicted SVR (0.72, 95% CI 0.59, 0.88, P<0.001). Detectable 4-week on-treatment HCV RNA≥15 IU/ml reduced SVR odds for both regimens (LDV/SOF ±RBV OR 0.49, 95% CI 0.41, 0.58, P<0.001; OPrD ±RBV OR 0.38, 95% CI 0.29, 0.50, P<0.001). Receipt of OPrD+RBV compared to LDV/SOF reduced odds of SVR (OR 0.70, 95% CI 0.62, 0.80, P<0.001). Mental health diagnosis did not impact likelihood of SVR.

CONCLUSIONS

The diversity and size of this cohort allowed for extensive examination of regimen-specific predictors of SVR. FIB-4>3.25 and detectable 4-week on-treatment HCV RNA had the greatest negative impact. African-American race, low or high BMI, and PPIs negatively impacted odds of SVR for LDV/SOF ±RBV. Mental health diagnoses did not.

摘要

背景

全口服丙肝治疗方案持续病毒学应答(SVR)的预测因素可为细致的治疗决策提供依据。我们评估了在常规治疗中接受来迪派韦/索磷布韦±利巴韦林(LDV/SOF±RBV)和奥比他韦/帕利哌韦/利托那韦+达沙布韦(OPrD)±RBV治疗的患者的治疗效果,并确定了SVR的预测因素。

方法

在任何退伍军人事务机构对21142例基因型1患者进行观察性、意向性治疗队列研究,这些患者开始接受8或12周的LDV/SOF±RBV治疗或12周的OPrD±RBV治疗。构建多变量逻辑回归模型以模拟SVR并确定预测因素。

结果

LDV/SOF的SVR为91.2%(9781/10720),LDV/SOF+RBV为89.6%(3266/3646),OPrD为91.7%(1197/1306),OPrD+RBV为87.8%(3365/3832)。对于LDV/SOF±RBV,非裔美国人(0.80,95%CI 0.70,0.92,P<0.001)、体重指数(BMI)<25(0.77,95%CI 0.66,0.90,P<0.001)、BMI≥30(0.77,95%CI 0.67,0.89,P<0.001)、质子泵抑制剂(PPI;0.81,95%CI 0.71,0.92,P<0.001)、失代偿性肝病(0.58,95%CI 0.45,0.74,P<0.001)和FIB4>3.25(0.60,95%CI 0.53,0.69,P<><>。对于OPrD±RBV,FIB-4>3.25对SVR有负向预测作用(0.72,95%CI 0.59,0.88,P<0.001)。治疗4周时可检测到的HCV RNA≥15 IU/ml降低了两种治疗方案的SVR几率(LDV/SOF±RBV的OR为0.49,95%CI 0.41,0.58,P<0.001;OPrD±RBV的OR为0.38,95%CI 0.29,0.50,P<0.001)。与LDV/SOF相比,接受OPrD+RBV治疗降低了SVR几率(OR 0.70,95%CI 0.62,0.80,P<0.001)。心理健康诊断不影响SVR的可能性。

结论

该队列的多样性和规模允许对SVR的特定治疗方案预测因素进行广泛研究。FIB-4>3.25和治疗4周时可检测到的HCV RNA产生的负面影响最大。非裔美国人种族、低BMI或高BMI以及PPI对LDV/SOF±RBV的SVR几率有负面影响。心理健康诊断则没有。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验